

**Table.** HIV Guideline Treatment Recommendations

GUIDELINE	LAST UPDATED	RECOMMENDED INITIAL REGIMENS	“ALTERNATIVE REGIMENS”*
DHHS <sup>1</sup>	May 2018	<ul style="list-style-type: none"> <li>✓ BIC/FTC/TAF</li> <li>✓ DTG/ABC/3TC</li> <li>✓ DTG + FTC/(TAF or TDF)</li> <li>✓ EVG/c/FTC/(TAF or TDF)</li> <li>✓ RAL + FTC/(TAF or TDF)</li> </ul>	<ul style="list-style-type: none"> <li>• DRV/c or DRV/r + FTC/(TAF or TDF)</li> <li>• ATV/c or ATV/r + FTC/(TAF or TDF)</li> <li>• DRV/c or DRV/r + ABC/3TC</li> <li>• ATV/c or ATV/r + ABC/3TC</li> <li>• EFV + FTC/(TAF or TDF)</li> <li>• RPV + FTC/(TAF or TDF)</li> <li>• RAL + ABC/3TC</li> <li>• DRV/r + RAL</li> <li>• LPV/r + 3TC</li> </ul>
IAS–USA <sup>2</sup>	July 2018	<ul style="list-style-type: none"> <li>✓ BIC/FTC/TAF</li> <li>✓ DTG/ABC/3TC</li> <li>✓ DTG + FTC/TAF</li> </ul>	<ul style="list-style-type: none"> <li>• DRV/c or DRV/r + FTC/(TAF or TDF)</li> <li>• EFV/FTC/TDF</li> <li>• EVG/c/FTC/(TAF or TDF)</li> <li>• RAL + FTC/(TAF or TDF)</li> <li>• RPV/FTC/(TAF or TDF)</li> </ul>
EACS <sup>3</sup>	October 2017	<ul style="list-style-type: none"> <li>✓ DTG/ABC/3TC</li> <li>✓ DTG + FTC/(TAF or TDF)</li> <li>✓ EVG/c/FTC/(TAF or TDF)</li> <li>✓ RAL + FTC/(TAF or TDF)</li> <li>✓ DRV/c or DRV/r + FTC/(TAF or TDF)</li> <li>✓ RPV/FTC/(TAF or TDF)</li> </ul>	<ul style="list-style-type: none"> <li>• RAL + ABC/3TC</li> <li>• EFV/FTC/TDF</li> <li>• EFV + ABC/3TC</li> <li>• ATV/c or ATV/r + FTC/(TAF or TDF)</li> <li>• ATV/c or ATV/r + ABC/3TC</li> <li>• DRV/c or DRV/r + ABC/3TC</li> <li>• DRV/c or DRV/r + RAL</li> </ul>
BHIVA <sup>4</sup>	2016 interim update	<ul style="list-style-type: none"> <li>✓ DTG + FTC/(TAF or TDF)</li> <li>✓ EVG/c/FTC/(TAF or TDF)</li> <li>✓ RAL + FTC/(TAF or TDF)</li> <li>✓ DRV/r + FTC/(TAF or TDF)</li> <li>✓ ATV/r + FTC/(TAF or TDF)</li> <li>✓ RPV/FTC/(TAF or TDF)</li> </ul>	<ul style="list-style-type: none"> <li>• EFV/FTC/TDF</li> <li>• DTG/ABC/3TC</li> <li>• EVG/c + ABC/3TC</li> <li>• RAL + ABC/3TC</li> <li>• DRV/r + ABC/3TC</li> <li>• ATV/r + ABC/3TC</li> <li>• RPV + ABC/3TC</li> </ul>
World Health Organization <sup>5,6</sup>	July 2018	<ul style="list-style-type: none"> <li>✓ DTG + TDF + 3TC or FTC</li> <li>✓ EFV + TDF + 3TC or FTC</li> </ul>	<ul style="list-style-type: none"> <li>• EFV or NVP + AZT + 3TC</li> <li>• EFV<sub>400</sub> + TDF + 3TC or FTC</li> <li>• NVP + TDF + 3TC or FTC</li> </ul>

ABC indicates abacavir; ATV, atazanavir; AZT, zidovudine; BHIVA, British HIV Association; BIC, bictegravir; c, cobicistat; DHHS, US Department of Health & Human Services; DRV, darunavir; DTG, dolutegravir; EACS, European AIDS Clinical Society; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; IAS–USA, International Antiviral Society–USA Panel; LPV, lopinavir; NVP, nevirapine; r, ritonavir; RAL, raltegravir; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine.

\*Recommended initial regimens in certain clinical situations in the DHHS guidelines or recommended initial regimens for individuals for whom generally recommended regimens are not available or not an option in the IAS–USA guidelines.